Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ZKK
|
||||
| Former ID |
DIB010311
|
||||
| Drug Name |
131I-81C6
|
||||
| Synonyms |
Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Brain cancer [ICD9: 191, 225.0; ICD10:C71, D33] | Terminated | [534731] | ||
| Company |
Duke University
|
||||
| Target and Pathway | |||||
| Target(s) | Tenascin | Target Info | [534731], [544064] | ||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| Ref 534731 | Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502. | ||||
| Ref 544064 | A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 April; 10(2): 182-189. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.